Clinical trial
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease
NCT07214571 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease
- Lead sponsor
- Shionogi
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 11, 2025
- Completion date
- December 30, 2026
- Enrollment
- 192 (estimated)
- Sites
- 87
Conditions
As the registry lists them; a condition with its own page is linked.